| __timestamp | ADMA Biologics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 17986000 |
| Thursday, January 1, 2015 | 6745968 | 32480000 |
| Friday, January 1, 2016 | 8494742 | 68081000 |
| Sunday, January 1, 2017 | 18092835 | 169906000 |
| Monday, January 1, 2018 | 22502922 | 248932000 |
| Tuesday, January 1, 2019 | 25910757 | 354100000 |
| Wednesday, January 1, 2020 | 35050817 | 433300000 |
| Friday, January 1, 2021 | 42896889 | 583300000 |
| Saturday, January 1, 2022 | 52458024 | 752700000 |
| Sunday, January 1, 2023 | 59020000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing insights
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and ADMA Biologics, Inc. from 2014 to 2023. Neurocrine Biosciences has consistently outpaced ADMA Biologics in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Neurocrine's SG&A expenses were nearly 15 times higher than ADMA's, highlighting its significant investment in administrative and sales functions. Over the decade, Neurocrine's expenses grew by approximately 490%, while ADMA's increased by about 1,120%, indicating a rapid expansion phase. This data provides a fascinating insight into how these companies allocate resources to support their growth strategies. Understanding these trends can offer investors and industry analysts a deeper perspective on the operational priorities of these biotech firms.
AstraZeneca PLC vs ADMA Biologics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? ADMA Biologics, Inc. or Evotec SE